Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Polartechnics makes debut in STI diagnostics market

This article was originally published in Clinica

Executive Summary

Diagnostics company Polartechnics is breaking into the global market for sexually-transmitted infection testing, after it clinched a deal for a modified version of its CerviScreen self-sampling device. Sydney, Australia-based Polartechnics has adapted the CervicScreen, originally designed for cervical screening purposes, so that the new device collects samples to test for STIs, including chlamydia, gonorrhoea and trichomoniasis. The company will make the STI self-sampling device available in Australia through Gribbles Pathology, a pathology services provider with a network of 43 labs across the continent. The product will be distributed in China and south-east Asia through retail pharmacies. Polartechnics added that it is also currently in talks to seal distribution deals for the product in Europe and the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel